BiotechTube

IFF flavor 316 282, Paracetamol, Pseudoephedrine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Upper Respiratory Infections

Conditions

Upper Respiratory Infections

Trial Timeline

May 1, 2012 → May 1, 2012

NCT ID
NCT01586962

About IFF flavor 316 282, Paracetamol, Pseudoephedrine

IFF flavor 316 282, Paracetamol, Pseudoephedrine is a phase 3 stage product being developed by Novartis for Upper Respiratory Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01586962. Target conditions include Upper Respiratory Infections.

What happened to similar drugs?

6 of 14 similar drugs in Upper Respiratory Infections were approved

Approved (6) Terminated (1) Active (8)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅BOTOXAbbVieApproved
✅Montelukast + PlaceboMerckApproved
✅diclofenac potassium + nimesulideNovartisApproved
✅Diclofenac gelNovartisApproved
✅AboBoNT-A + OnaBoNT-AIpsenApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01586962Phase 3Completed

Competing Products

20 competing products in Upper Respiratory Infections

See all competitors
ProductCompanyStageHype Score
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
31
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
ABBV-950 + BOTOX + Placebo for ABBV-950AbbViePhase 1
21
BOTOX + Placebo for BOTOXAbbViePhase 2
35
BOTOXAbbVieApproved
43
MK-3475 and BCGMerckPhase 2
42
Montelukast + PlaceboMerckApproved
43
Muntelukast + PlaceboMerckPhase 3
36
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tabletsNovartisPhase 3
40
diclofenac potassium + nimesulideNovartisApproved
35
Diclofenac gelNovartisApproved
43
IFF flavor 316 282, Paracetamol , Phenylephrine, GuaifenesinNovartisPhase 3
40
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + NivolumabGilead SciencesPhase 3
44
Azithromycin SRPfizerPhase 3
40
NivolumabBristol Myers SquibbPre-clinical
26
NivolumabBristol Myers SquibbPre-clinical
26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsPhase 2
27
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
AboBoNT-A + OnaBoNT-AIpsenApproved
40
Botulinum toxin type AIpsenPhase 3
37